2 Dividend Stocks to Buy for 2026 and Beyond

CVS Health, whose stock is up ~80% year-to-date, is executing margin-focused moves — streamlining its Medicare Advantage business and withdrawing Aetna from underperforming markets — while expanding customer offerings (ExtraCare Plus) and launching an AI care platform; management has increased dividends ~33% over five years and the stock yields ~3.4%. Abbott Laboratories announced a roughly $21 billion equity-value acquisition of Exact Sciences to bolster its diagnostics segment, complementing durable franchises such as FreeStyle Libre and MitraClip; as a Dividend King with broad product exposure, the deal should enhance Abbott's diagnostics growth and long-term shareholder returns.

Analysis

Market structure: CVS (CVS) and Abbott (ABT) are the direct beneficiaries — CVS from margin recovery after Medicare Advantage (MA) rationalization and operational levers that could restore 100–300 bps of operating margin over 12–24 months, and Abbott from scale in diagnostics after the ~$21B Exact Sciences (EXAS) buy that can add 100–200 bps to revenue growth over 2–3 years via cross-sell. Losers include pure-play retail rivals (e.g., WBA) and standalone diagnostics names that lose pricing power vs. an integrated ABT+EXAS. Healthcare demand remains inelastic, so supply shocks are unlikely; the key supply/demand shift is pricing power concentration in integrated players, which should compress credit spreads for high-grade healthcare paper and modestly damp risky hospital credit spreads.

Risk assessment: Tail risks include regulatory rejection or heavy remedy to ABT/EXAS (deal blocked or forced divestitures), MA reimbursement shocks that force CVS to cede further markets, or supply-chain disruption for CGM components; each could materially hurt EPS (>10% downside). Immediate effects (days) are deal-sentiment moves and spread compression; short-term (weeks–months) are earnings and regulatory filings; long-term (years) are integration, reimbursement, and competitive CGM adoption (expect 15–25% CAGR for Libre globally). Hidden dependencies: reimbursement policy cadence and commodity/semiconductor supply to devices; catalysts include Q4 earnings (30–60 days) and antitrust notifications (next 90 days).

Trade implications: Direct play — overweight ABT for 12–36 months for dividend + M&A upside; tactically buy CVS on pullbacks or sell covered calls to monetize volatility. Pair trade — long ABT vs short WBA (6–18 months) to capture diagnostic/insurer margin trends vs. retail pressures. Options — consider ABT 9–15 month LEAP calls or buy protective 3–6 month puts on a healthcare basket if you hold CVS into MA resets; target cost <2% portfolio for option hedges.

Contrarian angles: Consensus underestimates integration and reimbursement risk — Abbott may overpay for EXAS and see 5–10% EPS dilution in year 1 if revenue synergies lag. CVS’s 80% YTD run-up leaves mean-reversion risk; a 10–20% pullback would be a buying opportunity, not a panic signal. Historical parallel: vertical insurer+retailer integrations (post-CVS/Aetna) had multi-year operational drag before benefits; if MA exits reduce pharmacy fills in specific markets, retail comps could surprise to the downside.

Key Decisions for Investors

• Establish a 3–5% long core position in ABT within 30 days to capture FreeStyle Libre growth and EXAS synergies; as a leveraged alternative, buy 12–18 month LEAP call options (~1–2% portfolio notional) and trim if ABT rallies >25%.
• Initiate a 2–3% long position in CVS (CVS) but monetize with 1–3 month covered calls to boost yield; add to position on pullbacks of 12–15% from current levels or if operating margin expands >150 bps over two consecutive quarters.
• Enter a 1–2% pair trade: long ABT vs short WBA (equal notional) for a 6–18 month horizon to express diagnostics/insurer strength versus retail pharmacy margin pressure; cut the pair if ABT underperforms by >15% or WBA outperforms by >20%.
• Buy protective downside: allocate 1–2% of portfolio to 3–6 month ATM puts on a healthcare ETF (e.g., XLV) or buy puts on CVS sized to cap portfolio healthcare drawdown at ~10%; increase hedge if regulatory filings for ABT–EXAS indicate significant remedies within 90 days.
• Monitor three binary triggers over the next 90 days and act: (1) FTC/DOJ declaration on ABT–EXAS (if hostile, reduce ABT by 50%); (2) CMS MA rate guidance or CMS audit outcomes (if negative enough to erase >150 bps margin, trim CVS by 50%); (3) CVS quarterly cadence showing >150 bps YoY margin improvement (if confirmed, add another 2–3% to CVS).